In the News: ivWatch is anchor tenant at Tech Center Research Park in Newport News

Advancement of Region’s Tech Community Covered by Inside Business

ivWatch’s commitment to becoming the anchor tenant of Tech Center Research Park was covered recently in Inside Business. The article discusses the how the synergy between ivWatch departments and new tenants will inspire an evolution of the technology sector in Hampton Roads. ivWatch President and CEO Gary Warren discusses the attractive amenities of the space to retain and recruit employees and successfully execute the company’s business plan, where the Park’s Director, Jeff Johnson, says ivWatch will be a key driver in creating an innovative environment by attracting other high-tech operations to the area. Read the full article here.

ivWatch Announces Relocation Commitment to Accommodate Growth


Tech Center Research Park welcomes medical device company as anchor tenant

NEWPORT NEWS, Va., March 6, 2018 – ivWatch, the only provider of medical devices for the early detection of intravenous (IV) infiltrations and extravasations, announced today that it is moving forward with plans to relocate from their Hampton and Williamsburg facilities to anchor Newport News Tech Center Research Park‘s Building One. The move will increase operational efficiency by combining all departments, including manufacturing and research and development, under one roof.

“We are experiencing continued growth year after year in staff size, sales and manufacturing operations,” said Gary Warren, president and CEO of ivWatch. “The decision to move to the Research Park supports the execution of our business and recruiting plans. Within the next four years, we plan to add 150 new employees to support our international market-entry and expanding our sales activity in the U.S. through two leading healthcare group purchasing organization(GPO) contracts.”

The company has made substantial progress in developing, designing and commercializing a pioneering non-invasive biosensor technology. Terumo Corporation, one of the world’s leading medical device manufacturers and distributors, was recently named the exclusive distributor for ivWatch in Japan. Additionally, through “Breakthrough” and “Innovative” technology group purchasing contract awards from Premier and Vizient, the ivWatch Model 400 is more accessible to thousands of hospitals and healthcare systems across the U.S.

The Newport News Tech Center will be home to more than one million square feet of space across 11 planned buildings, punctuated by restaurants, shops, fitness clubs, biking trails and gathering spots. With a highly-skilled workforce, the addition of ivWatch to the Research Park will help foster and fuel the technology sector in the Hampton Roads area.

The new headquarter building is part of ivWatch’s investment in supporting their growing operations and customer base as well as the community.

“The best companies are those with access to research, influence and partners with resources you don’t have yet. As a young company in the medical device market, it’s essential to develop and pursue those types of resources to build a company in this tightly regulated industry,” said Warren. “We are proud of the success we’ve achieved, and this workplace will allow us to provide access to others by sharing our journey of how we turned research and data into a solution-based application used in leading hospitals across the country.”

Master building plans include prominent ivWatch signage on the exterior of the building, with ivWatch occupying more than 25,500 sq. ft. including manufacturing, warehouse space on the first floor, and state-of-the-art office space on the first and third floors. The company will keep their open floor plan concept which they’ve found facilitates interdepartmental collaboration. The building will include space for other tenants, co-working spaces and a business accelerator program.

The construction of the building is underway, with a target move-in date of late 2018.

To learn more about ivWatch, visit www.ivWatch.com. To learn more about Tech Center Research Park, visit innovateattechcenterva.com.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivWatch.com/

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

In the News: Expected Tech Center Anchor to Add 150 Jobs

New Headquarters and Planned Growth Featured in Daily Press and TidewaterBiz
The ivWatch commitment to a new headquarter building at Newport News Tech Center was covered in the Daily Press and TidewaterBiz article, “Expected Tech Center Anchor to Add 150 Jobs.” The announcement includes the company becoming the anchor tenant of the first building of the corporate research park, and ivWatch’s growth and recruitment plans over the next four years. ivWatch President and CEO Gary Warren discusses the demand for the company’s technology from recent contracts and partnerships and bringing visibility to tech talent in Hampton Roads. Read the full article here.

In the News: Training the Trainers to Ensure Customer Satisfaction

ivWatch Chief Nursing Officer Talks Product Support in MD+DI
ivWatch’s Susan Brown recently shared insights on device implementation in the Medical Device and Diagnostic Industry (MD+DI) article, “Training the Trainers to Ensure Customer Satisfaction.” In the piece, she taps on her clinical research experience and training program development for ivWatch to inform readers of best practices during the various stages of the device buying cycle. The article highlights device evaluations, training, implementation, and the need for high-quality medical devices to be accompanied by high-touch servicing models to keep customer satisfaction high. MD+DI is a resource for manufacturers of medical devices and in vitro diagnostic products with a mission to help medtech professionals develop, design, and manufacture products that comply with complex and demanding regulations and evolving market requirements.
Read her article here.

ivWatch Intellectual Property Grows with Three International Patents

Latest patent grants cover core product technologies

HAMPTON, Va., February 8, 2018 – ivWatch, the only provider of continuous monitoring devices for the early detection of peripheral intravenous (PIV) infiltrations and extravasations, recently had three patent applications granted by the Japanese and Australian Patent Offices expanding the company’s intellectual property portfolio.

“Today’s healthcare marketplace is growing increasingly competitive with the introduction of new devices and technologies, so we must continue to build on our successes in this space by protecting our innovations,” said Gary Warren, president and CEO of ivWatch. “Our philosophy regarding intellectual property is to aggressively protect our proprietary technology to expand our product portfolio and develop licensing opportunities with strategic partners.”

Granted Japanese Patent Application No. 2015-553708 is for a core technology regarding the geometry of ivWatch sensor heads – for both the fiber optic and electronic systems – which has secured ivWatch’s position as a first, and only, technology of its kind in the market. Optimal light angles and distances of the various sensor parts allow the technology to detect infiltrations with high sensitivity to aid healthcare providers in an early diagnosis of these most serious events during intravenous (IV) therapy.

Granted Japanese Patent Application No. 2015-510267 is for a second core technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, more commonly known as receptacles, may be independent of the dressings that cover infusion sites during IV therapy or may be integrated with those dressings. The granting of these applications comes just months after ivWatch entered into a licensing and distribution agreement with Terumo Corporation helping to advance patient safety in Japan and on a global scale.

Australian Patent No. 2013316021 is directed to a third core technology for mitigating the effects of tissue blood volume changes. The Australian patent corresponds to U.S. Patent No. 9,326,686, for solving motion issues related to continuous PIV therapy monitoring. The patent is directly related to the ability of the ivWatch Model 400 to reduce the number of “false” notifications helping combat an epidemic of clinicians becoming desensitized to alarms, many of which are false or clinically irrelevant.

These new grants are in addition to the two patents already in ivWatch’s intellectual property portfolio, which also includes numerous utility patent applications. This portfolio gives ivWatch the right to prevent others from making, using or selling our products in the U.S. and major international markets.

There is a rapid demand for breakthrough technology as more healthcare facilities focus on value-based care to lower costs and improve patient safety and satisfaction. IV infiltration and extravasation is a major problem as it can lead to serious medical complications and even amputation. The ivWatch Model 400 continuously monitors a patient’s PIV for evidence of infiltrations and extravasations, which occur when medication or fluid leaks into the surrounding tissue. Early detection of those failures via ivWatch biosensor technology helps to minimize injuries associated with this common complication of IV therapy.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivWatch.com/

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch to Participate in Society of Critical Care Medicine’s (SCCM) Critical Care Congress

The ivWatch team is returning to the Society of Critical Care Medicine’s (SCCM) Critical Care Congress on February 25-27, 2018 for the third consecutive year. The Society’s Congress embarks on their 47th annual event and remains the largest critical care event bringing together members of the multi-professional, multidisciplinary critical care field.

ivWatch representatives will be at booth 224 in the exhibit hall educating attendees about the latest technology advancements in peripheral IV therapy care. ivWatch shares in the Society’s mission of securing the highest quality care for all critically ill and injured patients. 

In previous years, we’ve met with several pediatric and neonatal intensive care unit teams as well as those in the operating room. Whether you are a department or patient safety director, sit on a value-analysis committee, or simply interested in learning about evidence-based ways to improve patient care, we invite you to stop by or reach out. We’ll have ongoing demonstrations of the ivWatch Model 400, the only medical device and biosensor technology that continuously monitors the IV site for the early detection of IV infiltrations to help improve patient safety and minimize patient harm.

We look forward to collaborating with critical care experts and internationally renowned faculty in a few weeks.

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest